Receptor-driven identification of novel human A₃ adenosine receptor antagonists as potential therapeutic agents.
The field of therapeutic application of the A₃ adenosine receptor (A₃AR) antagonists represents a rapidly growing and intense area of research in the adenosine field. Even if there are currently no A₃AR antagonists in clinical phases, in light of the plethora of biological effects attributed to A₃ARs, substantial efforts in medicinal chemistry have been directed toward developing antagonists for the A₃AR subtype. In this review, we summarize the more recent and promising evidences of the possible A₃AR application as drug candidates, and the role of the receptor-driven design in their in silico characterization.
Molecular Modeling Section (MMS), Dipartimento di Scienze Farmaceutiche, Università di Padova, via Marzolo, Padova, Italy.
Silvia
S
Paoletta
Stephanie
S
Federico
Giampiero
G
Spalluto
Stefano
S
Moro
D058918:Adenosine A3 Receptor Antagonists / Q000737:chemistry* / Q000494:pharmacology*; D015195:Drug Design; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D016296:Mutagenesis; D011485:Protein Binding; D043684:Receptor, Adenosine A3 / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*
D058918:Adenosine A3 Receptor Antagonists; D043684:Receptor, Adenosine A3